Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques

European Journal of Pharmacology

Volumn 372, Issue 1, 1999, Pages 49-56

  Nilsson, Torun ^a   Longmore, Jenny ^b   Shaw, David ^b   Pantev, Emil ^a   Bard, John A ^c   Branchek, Teresa ^c   Edvinsson, Lars ^a  

^a LUND UNIVERSITY   (Sweden)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^c H LUNDBECK A S   (Denmark)

Author keywords

5 HT(1B) receptor; 5 HT(2A) receptor; Coronary artery, human; Immunocytochemistry; Pharmacology, in vitro; RT PCR

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2 METHYLSEROTONIN; 3 (3 DIMETHYLAMINOPROPYL) 4 HYDROXY N [4 (4 PYRIDINYL)PHENYL]BENZAMIDE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 CARBAMOYLTRYPTAMINE; ALPHA METHYLSEROTONIN; DESMETHYLZOLMITRIPTAN; KETANSERIN; MESSENGER RNA; METITEPINE; NORZOLMITRIPTAN; RECEPTOR ANTIBODY; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 1 ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY CONSTRICTION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENCY; EPICARDIUM; GENE EXPRESSION; HEART ATRIUM; HEART VENTRICLE WALL; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; CARDIOVASCULAR SYSTEM; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KETANSERIN; METHIOTHEPIN; OXAZOLES; OXAZOLIDINONES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SUMATRIPTAN; TISSUE DISTRIBUTION; TRYPTAMINES; VASOCONSTRICTION;

EID: 0032953782     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00114-4     Document Type: Article

References (31)

1. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc. Natl. Acad. Sci. 90:1993;408-412.
2. 7) positively linked to adenylate cyclase. J. Biol. Chem. 268:1993;23422-23426.
3. Bax W.A., Renzenbrink G.J., Van Heuven-Nolsen D., Thijssen E.J.M., Bos E., Saxena P.R. 5-HT receptors mediating contractions of human isolated human coronary artery. Eur. J. Pharmacol. 239:1993;203-210.
4. Branchek T. Site-directed mutagenesis of serotonin receptors. Med. Chem. Res. 3:1993;287-296.
5. Brown E.G., Endersby C.A., Smith R.N., Talbot J.C.C. The safety and tolerability of sumatriptan: an overview. Eur. Neurol. 31:1991;339-344.
6. Connor, H.E., Beattie, D.T., 1996. 5-Hydroxytryptamine receptor subtypes and migraine. In: Sandler, M., Ferrari, M., Harnett, S. (Eds.), Migraine: Pharmacology and Genetics. Chapman & Hall, London, pp. 18-27.
7. 2 receptor activation. Eur. J. Pharmacol. 161:1989;91-94.
8. Dixon R., Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia. 17:1997;15-20. Suppl. 18.
9. Fenuik W., Humphrey P.P.A., Perren M.J., Watts A.D. A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists. Br. J. Pharmacol. 86:1985;697-704.
10. Ferro A., Longmore J., Hill R.G., Brown M.J. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br. J. Clin. Pharmacol. 40:1995;245-251.
11. Giorgi, L., Dixon, R., Touw, K., 1996. Cardiovascular safety of the novel antimigraine compound 311C90 [poster]. 7th international Headache Congress, Toronto.
12. Goadsby P.J., Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5-HT)-1D receptor agonist 311C90. Headache. 34:1994;394-399.
13. 1D receptor subtypes. Trends Pharmacol. Sci. 17:1996;103-105.
14. Hougton L.A., Foster J.M., Whorwell P.J., Morris J., Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet. 344:1994;985-986.
15. Hoyer D., Clerke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A. VII International union of pharmacology classification of receptors for 5-HT (serotonin). Pharmacol. Rev. 46:1994;157-196.
16. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. NeuroReport. 8:1997;2237-2240.
17. 2 receptors in serotonin-induced contraction of human isolated coronary arteries. Circulation. 90:1994;1141-1153.
18. Lloyd D.K., Simmons V. Adverse reactions associated with sumatriptan. Lancet. 341:1993;1092.
19. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia. 17:1997;833-842.
20. Maassen Van Den Brink A., Reekers M., Bax W.A., Ferrari M.D., Saxena P.R. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 98:1998;25-30.
21. MacIntyre P.D., Bhargave B., Hogg K.J., Gemmill J.D., Hillis W.S. The effect of i.v. sumatriptan, a selective 5-HT-1-receptor agonist, on central haemodynamics and the coronary circulation. Br. J. Clin. Pharmacol. 34:1992;541-546.
22. 1B/1D agonist for migraine. Cephalalgia. 17:1997;4-14. Suppl.
23. 1B/1D receptor partial agonist, 311C90 (Zolmitriptan). Br. J. Pharmacol. 121:1997;157-164.
24. Ottervanger J.P., Paalman J.J.A., Boxman G.L., Stricker B.H.C. Transmural myocardial infarction with sumatriptan. Lancet. 341:1993;861-862.
25. Ploskler G.L., McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 47:1994;622-651.
26. 1F receptor activation. Br. J. Clin. Pharmacol. 47:1999;75-82.
27. Saeber, E., On, N., Phillips, S., Churchus, R., Posner, J., Rolan, P., 1996. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. 41, 141-147.
28. Saxena P.R., Villalon C.M. 5-hydroxytryptamine, a chameleon in the heart. Trends Pharmacol. Sci. 12:1991;223-227.
29. 7 receptors mediating tachycardia in the cat. Br. J. Pharmacol. 121:1997;1187-1195.
30. Visser W.H., Klein K.B., Cox R.C., Jones D., Ferrari M.D. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine. Neurology. 46:1996;522-526.
31. Willet F., Curzen N., Adams J., Armitage M. Coronary vasospasm induce by subcutaneous sumatriptan. Br. Med. J. 304:1992;1415.